Abstract
Selenium compounds, in both inorganic and organic forms have been explored for development as radioprotectors, agents used to minimize the deleterious effects of radiation. Most of the research in this direction has been focused on inorganic selenium, including several clinical studies where selenium supplementation yielded useful outcomes in cancer patients undergoing radiotherapy. Since organic selenium is less toxic than inorganic selenium, researchers are now focusing on the development of organoselenium compounds for radioprotection. Both natural and synthetic organoselenium compounds are being examined and one such water-soluble selenium compound, 3,3′-diselenodipropionic acid (DSePA) developed by our group, showed promising activity at pre-clinical stages. These results, along with the current status and future scope of research, are discussed in this chapter.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
